

**PRECAUTIONS**

**Analgesia during anesthesia:** ALFAXAN MULTIDOSE IDX is not an analgesic and appropriate analgesia should be provided to the patient for painful procedures.

**Rapid arousal:** Careful monitoring of the patient is necessary due to possibility of rapid arousal.

**Apnea:** Apnea may occur following IV administration of an induction dose, maintenance dose or a dose administered during transition to inhalant maintenance anesthesia of ALFAXAN MULTIDOSE IDX, especially with high doses and rapid administration. Endotracheal intubation, oxygen supplementation and intermittent positive pressure ventilation (IPPV) should be administered to treat apnea and associated hypoxemia in the appropriate species.

**Blood Pressure:** ALFAXAN MULTIDOSE IDX can exacerbate the myocardial depressive and vasodilatory effects of inhalant anesthetics resulting in hypotension. Preanesthetics can potentiate the effect of ALFAXAN MULTIDOSE IDX resulting in more pronounced changes in blood pressure. Transient hypertension has also been observed with ALFAXAN MULTIDOSE IDX administration, possibly due to elevated sympathetic activity in the patient. It is prudent to monitor blood pressure whenever possible.

**Body temperature:** Steps should be taken to maintain the normal physiological temperature of the patient during anesthesia. Supplemental heat, appropriate for the species, should be provided to maintain acceptable core body temperature until full recovery.

**Breeding animals:** Alfaxalone crosses the placenta, and as with other general anesthetic agents, the administration of ALFAXAN MULTIDOSE IDX may be associated with neonatal depression.

**Compromised or debilitated animals:** Caution should be used in animals with cardiac, respiratory, renal or hepatic impairment, or in hypovolemic or debilitated animals and geriatric animals.

**ADVERSE REACTIONS**

Specific adverse reactions described in the referenced literature are listed in the Dosage and Administration section of the product insert.

**CONTACT INFORMATION**

For a copy of the Safety Data Sheet or to report adverse reactions, call Zoetis Inc. at 1-888-963-8471. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or at [www.fda.gov/reportanimaldrugs](http://www.fda.gov/reportanimaldrugs).

**OVERDOSE**

Rapid administration, accidental overdose, or relative overdose due to inadequate dose sparing of ALFAXAN MULTIDOSE IDX in the presence of preanesthetics may cause cardiopulmonary depression. Respiratory arrest (apnea) may be observed. In cases of respiratory depression, stop drug administration, establish a patent airway, and initiate assisted or controlled ventilation with pure oxygen. Cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents or other techniques as appropriate for the observed abnormality.

**STORAGE INFORMATION:** Store at controlled room temperature 20°C - 25°C (68° to 77°F) with excursions between 15° and 30°C (59° and 86°F). ALFAXAN MULTIDOSE IDX contains preservatives. The product can be used for 56 days after broaching the vial. Any unused ALFAXAN MULTIDOSE IDX remaining after 56 days should be discarded.

**HOW SUPPLIED:** ALFAXAN MULTIDOSE IDX is supplied in 10 mL and 20 mL multiple-dose vials containing 10 mg alfaxalone per mL.

ALFAXAN is a registered trademark of Jurox Pty Ltd.

Manufactured in Australia by Jurox Pty Ltd.

Distributed by: **zoetis**

Zoetis Inc.  
Kalamazoo, MI 49007

**LIST OF REFERENCES**

- Sheehan TS, Baker RT, Hammerley G, Hollis K, Elton J, Holt P. A preliminary investigation into the chemical restraint of selected Australian squamate species with Alfaxalone. *J Herpetol Med Surg* 2011;21(23):63-77.
- Bertelsen MF, Sauer CR. Alfaxalone anaesthesia in the green iguana (*Iguana iguana*). *Vet Anaesth Analg* 2011;38(5):461.
- Knotek Z, Hrdá L, Knotková Z, Tmavka S. Baláž V. Alfaxalone anaesthesia in the green iguana (*Iguana iguana*). *ACTA VET BRNO* 2013;82:109-114.
- Rowland MN. Fibrosis myopathy of the temporal muscles causing locking in a veiled chameleon (*Chamaeleo calyptratus*). *Vet Rec* 2016;169:103.
- Doss GA, Fink DM, Sladek KK, Marc M. Comparison of subcutaneous dexmedetomidine-midazolam versus alfaxalone-midazolam sedation in leopard geckos (*Eublepharis macularius*). *Vet Anaesth Analg* 2017;44(5):1175-1183.
- Moreira M, Díazguerra M, Spadola F, Oliveri M, Knotková Z, Knotek Z. Intravenous alfaxalone anaesthesia in a leopard gecko (*Eublepharis macularius*). *J Expt Vet Med* 2018;27(3):1114.
- Hoffman EM, Garrett K, Donnelly RT. Premedication causing clonic lapses in a parenteral monitor (*Venomous iguana*). *Australian Veterinary Practitioner* 2017;47(4):117-120.
- Knotek Z. Induction to inhalant anaesthesia in agamid lizards with alfaxalone. *Veterinari Medicina* 2017;20(1):41-43.
- Perrin KL, Bertelsen MF. Intravenous alfaxalone and propofol anaesthesia in the bearded dragon (*Pogona vitticeps*). *Herpetol Med Surg* 2017;27(3):123-126.
- Jameson LE, Williams CJH, Bertelsen MF, Wang T. Anesthetic induction with alfaxalone in the ball python (*Python regius*): dose response and effect of injection site. *Vet Anaesth Analg* 2018;45(3):329-337.
- Stehli-Hedreth B, Clark-Price SC, Keating SJ, Graham LF, Chimadura SK, Schaeffer E. Effect of intracardiac administration of alfaxalone on the righting reflex and tactile stimulus response of common garter snakes (*Thamnophis sirtalis*). *Am J Vet Res* 2019;80(2):144-151.
- Knotek Z. Alfaxalone as an inductive agent for anaesthesia in terrapins and tortoises. *Vet Rec* 2014;275(3):327.
- Kischinevsky M, Duse A, Wang T, Bertelsen MF. Intramuscular administration of alfaxalone in red-eared sliders (*Trachemys scripta elegans*)—effects of dose and body temperature. *Vet Anaesth Analg* 2013;40(1):13-20.
- Phillips BE, Pownell P, Lewbart GA, Christiansen EF, Harris CA. Effects of alfaxalone administered intravenously to healthy young loggerhead sea turtles (*Caretta caretta*) at three different doses. *J Am Vet Med Assoc* 2017;250(8):909-917.
- Hansen RL, Bertelsen MF. Assessment of the effects of intramuscular administration of alfaxalone with and without medetomidine in horses' tortoises (*Testudo horsfieldii*). *Vet Anaesth Analg* 2013;40(6):687-695.
- Romeijer J, Beaupré H, Laniesse D, Birch SM, Mackenzie S, Melville J, Moen N. Vomiting and gastrointestinal obstruction in a red-footed tortoise (*Chelonoidis carbonarius*). *J Herpetol Med Surg* 2016;26(1):2-35.
- Perpignani D, Martínez M, Sáenz A, Barral G, Di Giuseppe M, Orós J, Costa T. Correlation between endoscopic sex determination and gonad histology in pond sliders, *Trachemys scripta* (*Reptilia: Testudinidae*). *Acta Herpetologica* 2016;11(1):91-94.
- Hedler J, Woods E, Estwell K. The use of negative pressure wound therapy following subcarapacial abscess excision in a tortoise. *J Small Anim Pract* 2013;54(11):610-613.
- Adami C, O'Donnell D, Casoni D. Alfaxalone-butorphanil versus alfaxalone-morphone combination for immersion anaesthesia in oriental field toads (*Bombina orientalis*). *Lab Anim* 2016;50(3):204-211.
- Sládová K, Lánsky J, Johnson RS, Vogelzang J. Evaluation of intramuscular alfaxalone in three Australian frog species (*Litoria caerulea*, *Litoria aurea*, *Litoria boophis*). *J Herpetol Med Surg* 2014;24(1-2):36-42.
- McMillan MW, Lecce FA. Immersion and branchial/traumatic epiphora in anesthetized alfaxalone in a Mexican axolotl. *Vet Anaesth Analg* 2013;38(6):192-193.
- Bauquier SH, Greenwood J, Whittam T. Removal of retrobulbar hemangioma in a goldfish (*Carassius auratus*). *Aquaculture* 2013;396-399:119-123.
- O'Hagan RL, Bailey KM, Lockett GA, Leverett GA, Posner J. The efficacy of alfaxalone for immersion anesthesia in koi carp (*Cyprinus carpio*). *Vet Anaesth Analg* 2014;41(4):398-405.
- Bugman AM, Langer PT, Hadzima E, Rivas AE, Mitchell EA. Evaluation of the anesthetic efficacy of alfaxalone in Oscar fish (*Astronotus ocellatus*). *Am J Vet Res* 2016;77(3):239-244.
- Ferry J, Laikeas C, Keates H, McEvon M, Woldeyohanes S, Perkins N, Goodwin W. Comparison of two formulations of alfaxalone in laboratory zebrafish (*Danio rerio*) for use in immersion anaesthesia. Oral abstract. 25th International Veterinary Emergency and Critical Care Society (IVECCS) Symposium, September 7th, 2019 Washington, D.C., USA. Session 17.
- Balko JA, Lindemann DA, Allender MC, Chinadurai SK. Evaluation of the anesthetic and cardiorespiratory effects of intramuscular alfaxalone administration and isoflurane in budgerigars (*Melopsittacus undulatus*) and comparison with manual restraint. *J Am Vet Med Assoc* 2019;254(12):1427-1435.
- Escalante GC, Ballo JA, Chinadurai SK. Comparison of the sedative effects of alfaxalone and butorphanil-midazolam administered intramuscularly in budgerigars (*Melopsittacus undulatus*). *J Av Med Surg* 2018;32(4):279-285.
- Perrin RL, Nielsen JB, Thomasen EM, Bertelsen MF. Alfaxalone anaesthesia in the Bornean frog (*Limnonectes laevis*). *Zoo Wildl Med* 2017;8(4):1146-1153.
- Villaverde-Morillo S, Benito J, García-Sánchez R, Martín-Jurado O, Gómez de Segura JA. Comparison of isoflurane and alfaxalone (Alfaxan) for the induction of anesthesia in flamingos (*Phoenicopterus roseus*) undergoing orthopedic surgery. *Zoo Wildl Med* 2014;45(2):361-366.
- Baldwin Y. Assessment of alfaxalone as anesthetic induction agent in mute swans (*Cygnus olor*). Submitted in part fulfillment of the requirements for the Royal College of Veterinary Surgeons' Diploma in Zoological Medicine 2014-168.
- Gaudie F, Volant J, De Benedictis GM. Alfaxalone anaesthesia in Lemur catta following dexmedetomidine-butorphanil-midazolam sedation. *Vet Anaesth Analg* 2018;45(3):351-357.
- Passarelli RL, MG, Gamberale S, Ballo S, Kumar K, Bellingham MC. Plasma pharmacokinetics of alfaxalone after a single intraperitoneal or intravenous injection of Alfaxan® in rats. *J Vet Pharmacol Ther* 2013;36(5):5180.
- Reynolds J, Song SK, Tamari E, Barbee RW. Hypersensitivity and vulnerability to hemorrhagic shock in a rat model. *Shock* 2015;43(2):148-156.
- Arenillas M, Gómez de Segura JA. Anesthetic effects of alfaxalone administered intraperitoneally alone or combined with dexmedetomidine and fentanyl in the rat. *Lab Anim* 2018;52(6):588-598.
- White KL, Palau J, Gómez de Segura JA. Clinical evaluation of the pharmacokinetics and pharmacodynamics of intravenous alfaxalone in cyclodextrin in male and female rats following a loading dose and constant rate infusion. *Vet Anaesth Analg* 2017;44(4):865-875.
- d'Onise D, Marino E, Novello J, Lanaro E, Monticelli P, Adamini C. Sedative effects of intramuscular alfaxalone in pet guinea pigs (*Cavia porcellus*). *Vet Anaesth Analg* 2018;45(2):183-189.
- Doerning CM, Bradley MP, Lester PA, Nowland MH. Effects of subcutaneous alfaxalone alone and in combination with dexmedetomidine and buprenorphine in guinea pigs (*Cavia porcellus*). *Vet Anaesth Analg* 2018;45(5):658-666.
- Bericz M, Langlois J, Dunn M, Hélie P, Burns P, Gara-Bovin C. Cytological analysis of bronchoalveolar lavage fluid acquired by bronchoscopy in healthy ferrets: A pilot study. *Can J Vet Res* 2016;80(1):74-80.
- Thas I. Acquired salivary mucocele in two domestic ferrets (*Mustela putorius* furo). *Vet Case Rep* 2016;14:2-8.
- Giral M, García-Olmo DC, Gómez de Segura JA. Anesthetic effects in the ferret of alfaxalone alone and in combination with medetomidine or tramadol: A pilot study. *Lab Anim* 2014;48(4):313-320.
- Vogelzang E, Gómez de Segura JA. Anesthetic effects of alfaxalone in pet guinea pigs (*Cavia porcellus*). *Vet Anaesth Analg* 2018;45(2):183-189.
- McInnes LM, Gillett A, Ryan UM, Austin J, Campbell RS, Hanger J, Reid SA. Trypanosoma irwini n. sp (Sarcostigliphoridae: Trypanosomatidae) from the koala (*Phascolarctos cinereus*). *Parasitology* 2009;136(8):875-885.
- McInnes LM, Hanger J, Simmons G, Reid SA, Ryan UM. Novel trypanosoma trypanosoma gigillettii sp. (*Euglenozoia: Trypanosomatidae*) and the extension of the host range of Trypanosoma copemani to include the koala (*Phascolarctos cinereus*). *Parasitology* 2011;138(1):59-70.
- McInnes LM, Gillett A, Hanger J, Reid SA, Ryan UM. The potential impact of native Australian trypanosome infections on the health of koalas (*Phascolarctos cinereus*). *Parasitology* 2011;138(7):873-883.
- Markay B, Wan C, Hanger J, Phillips C, Timms P. Use of quantitative real-time PCR to monitor the shedding and treatment of chlamydia in the koala (*Phascolarctos cinereus*). *Vet Microbiol* 2007;120(3-4):334-342.
- Waugh C, Khan SA, Carver S, Hanger J, Loader J, Polkinghorne A, Beagley K, Timms P. A prototype recombinant protein-based Chlamydia pecorum vaccine results in reduced chlamydial burden and less clinical disease in free-ranging koalas (*Phascolarctos cinereus*). *PLoS One* 2016;11(1):1-9.
- Liddle Y, Varaman J, Bernay M. Anterior chamber collapse syndrome in a koala. *Aust Vet J* 2014;92(5):179-182.
- Bouts T, Karunaratne D, Berry D, Dodds J, Gauthys F, Routh A, Taylor P. Evaluation of medetomidine-alfaxalone and medetomidine-ketamine in semi-free ranging Bennett's wallabies (*Macropus rufogriseus*). *J Zoo Wildl Med* 2011;42(4):617-622.
- del Álamo AM, Mandsager RE, Riebold TW, Payton ME. Evaluation of intravenous administration of alfaxalone, propofol, and ketamine-diazepam for anesthesia in alpacas. *Vet Anaesth Analg* 2015;42(1):72-82.

Revised: April 2023

**FOR ANIMAL USE ONLY****Alfaxan® Multidose IDX ****(alfaxalone) 10 mg/mL Injectable Solution**

For use as an injectable sedative and anesthetic in multiple non food-producing minor species.

**CAUTION:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**LEGAL STATUS:** In order to be legally marketed, a new animal drug intended for a minor species must be Approved, Conditionally Approved, or Indexed by the Food and Drug Administration. THIS PRODUCT IS INDEXED—MIF 900-031. EXTRALABEL USE IS PROHIBITED.

This product is not to be used in animals for use as food for humans or food-producing animals.

**DESCRIPTION**

ALFAXAN MULTIDOSE IDX contains alfaxalone, a neuroactive steroid molecule with properties of a general anesthetic. Alfaxalone is chemically described as 3- $\alpha$ -hydroxy-5- $\alpha$ -pregnane-11,20-dione, and has a molecular weight of 332.5. The primary mechanism for the anesthetic action of alfaxalone is modulation of neuronal cell membrane chloride ion transport, induced by binding of alfaxalone to GABA<sub>A</sub> ( $\gamma$ -aminobutyric acid) cell surface receptors. This product contains the following preservatives: chlorocresol (0.1% w/v), benzethonium chloride (0.02% w/v) and ethanol (15% w/v).

**INDICATIONS**

ALFAXAN MULTIDOSE IDX is indicated as a sedative and anesthetic in multiple minor species\*. More specifically, ALFAXAN MULTIDOSE IDX is indicated for the following:

- For sedation and anesthesia in captive reptiles, excluding any food-producing species\*\*
- For sedation and anesthesia in captive amphibians, excluding any food-producing species\*\*
- For sedation and anesthesia in ornamental fish, including species used in research such as the zebrafish
- For sedation and anesthesia in captive species and pet birds in the orders Psittaciformes, Passeriformes, and Columbiformes, excluding any food-producing species\*\*
- For sedation and anesthesia in non-human primates
- For sedation and anesthesia in captive rodents
- For sedation and anesthesia in captive mustelids
- For sedation and anesthesia in captive marsupials
- For induction of anesthesia and immobilization in captive minor species ungulates, excluding any food-producing species\*\*

Use only when there is reasonable certainty that the treated animal will not be consumed by humans or food-producing animals.

\* The term "minor species" means animals other than humans that are not major species. "Major species" means cattle, horses, swine, chickens, turkeys, dogs and cats.

\*\* As used on this label, a "food-producing minor species" is considered to be a minor species of which some members are bred, cultured, farmed, ranched, hunted, caught, trapped or otherwise harvested for the purpose of having the animals or edible products of the animals commercially distributed for consumption by humans or food-producing animals in the United States.

**DOSAGE AND ADMINISTRATION**

When administering ALFAXAN MULTIDOSE IDX by intravenous injection administer slowly to effect, titrating administration against the response of the patient. Rapid administration of ALFAXAN MULTIDOSE IDX may be associated with an increased incidence of cardiorespiratory depression or apnea. The use of preanesthetics may reduce the ALFAXAN MULTIDOSE IDX induction dose. The choice and the amount of phenothiazine, alpha<sub>2</sub>-adrenoceptor agonist, benzodiazepine or opioid will influence the response of the patient to an induction dose of ALFAXAN MULTIDOSE IDX.

When using ALFAXAN MULTIDOSE IDX, patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available.

ALFAXAN MULTIDOSE IDX contains preservatives. Use within 56 days of first puncture. Any unused ALFAXAN MULTIDOSE IDX remaining after 56 days should be discarded.

The following tables outline the dosage and administration of ALFAXAN MULTIDOSE IDX for the indicated species by major group. The doses are representative of doses published in the literature. Veterinarians are advised to consult the published literature before use of the product (see List of References at end of product insert).

**REPTILES****Lizards**

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Blotched Bluetongue Lizard	9 mg/kg; IV	None	Ventral coccygeal vein; anesthesia not achieved in all cases		1
					1
					1
					1
					1
Green Iguana	20 mg/kg; IM 5 mg/kg; IV	None	Anesthesia		2
Veiled Chameleon	3 mg/kg; IV	None	Anesthesia		3
Leopard Gecko	15 mg/kg; SC 5 mg/kg; IV	Midazolam 1 mg/kg; SC	Deep sedation Anesthesia		4
Perentie Monitor	5 mg/kg; IV	None	Anesthesia		7
Bearded Dragon	5 mg/kg; IV 12 mg/kg; IV	Meloxicam 1 mg/kg + Butorphanol 2 mg/kg; IM or Tramadol 10 mg/kg; IM None	Anesthesia		8

**Turtles and Tortoises**

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Red Eared Slider Turtle	9 mg/kg; IV	None	Ventral coccygeal vein; anesthesia		1
					1
					1
					1
Ball Python	20 mg/kg; IM	None	Anesthesia (cranial injection site required)		10
Garter Snake	30 mg/kg; Intracoelomic	None	Loss of righting reflex		11

**Black ●**

**PRODUCT: US-Alfaxan Multidose IDX - LFT - 471645**

**MODIFICATION DATE: 20 April 2023 1.22 pm**

**DIMENSIONS: 240 x 224 mm spread (folded to 120 x 28 mm)**

**FRONT FACE (PAGES 1 & 4)**

471645

Turtles and Tortoises continued

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Russian Tortoise	5 mg/kg; IV	Meloxicam 1 mg/kg; IM and Butorphanol 2 mg/kg; IM	Anesthesia		12
	10 mg/kg; IM	Medetomidine 0.05 mg/kg; IM	Moderate/deep sedation; minimal analgesia	Bradycardia was observed with this combination of drugs	15
	20 mg/kg; IM	Medetomidine 0.1 mg/kg; IM	Deep sedation/anesthesia; variable analgesia		
Red Footed Tortoise	10 mg/kg; IM	Midazolam 1 mg/kg and Hydromorphine 0.5 mg/kg; IM (front legs)	Anesthesia		16
Pond Sliders	10 mg/kg; IV	None	Via subcarapacial vein; Anesthesia		17
Spur-Thighed Tortoise	10 mg/kg; IV	Morphine 1.5 mg/kg and Meloxicam 0.2 mg/kg; SC	Via jugular vein; Anesthesia		18

AMPHIBIANS

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	General Comments	Precautions/ Adverse Reactions	Reference Number
Oriental Fire Bellied Toad	30 mg/L H <sub>2</sub> O*; immersion	Butorphanol 25 mg/L H <sub>2</sub> O*; immersion (butorphanol combined with ALFAXAN MULTIDOSE IDX in same bath)	Surgical anesthesia was observed in both treatment groups.		19
	30 mg/L H <sub>2</sub> O*; immersion	Morphine 50 mg/L H <sub>2</sub> O*; immersion (morphine combined with ALFAXAN MULTIDOSE IDX in same bath)	The baths were adjusted to pH 7±0.2 with sodium bicarbonate, 8.4%. One third of the toad's surface area was immersed to avoid drowning.		
Australian Frog	20-30 mg/kg; IM	None	Anesthesia		20
Axolotl	5 mg/L H <sub>2</sub> O*; first immersion then continuous irrigation of the gills and skin after the axolotl was removed from the bath	None	The anesthetic bath was prepared to pH 6.5. Additional 30 µl drops of stock ALFAXAN MULTIDOSE IDX were applied to gills when required. Mild sedation was produced with initial immersion and anesthesia produced with subsequent drops.		21

\* Anesthetic baths were prepared using dechlorinated mineral water at room temperature

FISH

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Goldfish	0.5, 2.5 & 7.5 mg/L H <sub>2</sub> O*; immersion	None	Sedation at 0.5 and 2 mg/L. Anesthesia at 5 and 7.5 mg/L		22
	5 mg/L H <sub>2</sub> O; immersion followed by continuous gill irrigation with 5 mg/L H <sub>2</sub> O	None	Anesthesia		23
Koi	10 mg/L H <sub>2</sub> O*; immersion followed by continuous gill irrigation with 1 or 2.5 mg/L H <sub>2</sub> O	None	All fish anesthetized. Opercular movement observed in 4 of 6 fish at 2.5 mg/L H <sub>2</sub> O		24
Oscar Fish	5 mg/L H <sub>2</sub> O*; immersion	None	Anesthesia		25
Zebrafish	10 mg/L H <sub>2</sub> O*; immersion	None	Anesthesia		26

^ Water tanks at temperature (72-77°F); pH (6.8-7.2); osmolality (38-45 mOsm/L)

# Declorinated water at temperature (63-65°F); pH (6.9-7.6), total ammonia (0.0-0.25 mg/L); nitrate (0.0-5.0 mg/L)

¤ Declorinated water at temperature 77°F

§ Water tank at temperature 80°F; pH 7.9

BIRDS

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Budgerigar	10 mg/kg; IM	None	Sedation		27
	15 mg/kg; IM	None	Sedation		28
Bengalese Finch	10, 30 & 50 mg/kg; SC	Midazolam 0.7 mg/kg or Butorphanol 1 mg/kg; SC combined with 30 mg/kg ALFAXAN MULTIDOSE IDX; SC	Dose dependent response in duration of recumbency. Addition of midazolam or butorphanol produced a further increase in the duration of anesthesia.		29
Flamingo	2 mg/kg; IV	Isoflurane used for maintenance of anesthesia	Induction of anesthesia		30
Mute Swan	10 mg/kg; IV	Isoflurane used for maintenance of anesthesia	Induction of anesthesia	Induction apnea (<1 breath/30 sec) was observed in 12/27 swans or 44%	31

NON-HUMAN PRIMATES

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Ring Tailed Lemur	Initially 0.5 mg/kg; IV	Dexmedetomidine 0.015 mg/kg, Butorphanol 0.2 mg/kg; all IM	Bolused to effect until endotracheal intubation completed		32
Macaque	10 mg/kg; IM	Diazepam 3 mg/kg and Atropine 0.2 mg/kg; IM	Supplemental doses of 5 mg/kg Alfaxan Multidose IDX administered IV to maintain anesthesia		33
Common Marmoset	12 mg/kg; IM	None	Sedation		34
	15 mg/kg; IM	None	Anesthesia		35
	12-18 mg/kg; IM	Diazepam 0.25 mg/kg; IM	Anesthesia		36
	18.5 mg/kg; IM	None	Anesthesia		37
	10.6 ± 1.6 mg/kg; IM	None	3.2±1.2 mg/kg administered IV after the IM dose		38

RODENTS

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Mice	15-20 mg/kg; IV	None	Anesthesia maintained with 0.25-0.75 mg/kg/min; IV		39
	80 mg/kg; IP	Xylazine 10 mg/kg; IP	Longer sleep times observed in female vs. male mice with ALFAXAN MULTIDOSE IDX ± xylazine IP	Mild seizure-like activity appeared in some mice	40

Rodents continued

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Mice	60 mg/kg; SC	Medetomidine 0.3 mg/kg and Butorphanol 5 mg/kg; SC	Anesthesia	"Medetomidine should be used with caution in male mice (obstructive uropathy)	41
	10-12 mg/kg; IV	None	Anesthesia maintained with 0.25-0.75 mg/kg/min; IV		39
	2-5 mg/kg; IV	None	Anesthesia produced IV	A 30% failure rate for anesthesia observed IP.	42
	20 mg/kg; IP	None	Maintenance of anesthesia		43
	30 mg/kg/hr; IV	None	Anesthesia		44
	25 mg/kg; IP (females)	Dexmedetomidine 0.05 mg/kg; IP or Dexmedetomidine 0.05 mg/kg + Fentanyl 0.1 mg/kg; IP	Males rats appeared to require more ALFAXAN MULTIDOSE IDX than female rats to produce a similar duration of anesthesia		
	75 mg/kg; IP (males)	1.7 mg/kg/min for 2.5 min IV (induction of anesthesia)	Anesthesia maintained at 0.75 mg/kg/min; IV		45
Guinea Pig	5 mg/kg; IM	None	Sedation		46
	20 mg/kg; SC	+/- Dexmedetomidine 0.25 mg/kg; SC and Buprenorphine 0.05 mg/kg; SC	Sedation		47

% Wells S, et al. Urethral obstruction by seminal coagulum is associated with medetomidine - ketamine anesthesia in male mice on C57BL/6J and mixed genetic backgrounds. Am Assoc Lab Anim Sci 2009;48(3):296-299.

FERRETS

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Ferret	Butorphanol 0.1 mg/kg and midazolam 1 mg/kg; IM as premedication		Anesthesia maintained with 3 - 15 mg/kg/hr ALFAXAN MULTIDOSE IDX		48
	5 mg/kg; IV	Dexmedetomidine 0.05 mg/kg; SC as premedication	Anesthesia		49
	5 mg/kg; IV	None	Anesthesia	Medetomidine 0.02 mg/kg; IM as premedication	50
	2.5 mg/kg; IV	Medetomidine 0.02 mg/kg; IM as premedication			

MARSUPIALS

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Koala	3 mg/kg; IM	None	Anesthesia maintained with isoflurane in oxygen		51, 52, 53, 54, 55, 56
	2 mg/kg; IM	None	Anesthesia maintained with isoflurane in oxygen		57
	1.5 mg/kg; IV	None	Anesthesia		51
Wallaby	5 mg/kg; IM	Medetomidine 0.1 mg/kg; IM	Anesthesia. Drugs administered together in a dart.		58
Kangaroos and Wallabies	5-8 mg/kg; IM	None	Anesthesia		51
	1.5-3 mg/kg; IV	None	Rapid and short duration of anesthesia produced.		51
Possums and Gliders	5-8 mg/kg; IM	None			
Wombats	3-5 mg/kg; IM	None	Anesthesia		51

MINOR SPECIES UNGULATES

Common Name	ALFAXAN MULTIDOSE IDX Dose & Route	Concomitant Drug(s) Dose & Route	Outcome / Comments	Precautions/ Adverse Reactions	Reference Number
Alpaca	2.1 mg/kg; IV	None	Anesthesia achieved but poor quality of recovery observed.	Premedication is indicated prior to induction of anesthesia. Premedication will aid in induction of anesthesia and improve the quality of recovery in short procedures.	59

DRUG INTERACTIONS

No specific preanesthetic is either indicated or contraindicated with ALFAXAN MULTIDOSE IDX. The necessity for and choice of preanesthetic is left to the discretion of the veterinarian. Preanesthetic doses may be lower than the label directions for their use as a single medication. ALFAXAN MULTIDOSE IDX is compatible with benzodiazepines, opioids, alpha-agonists, and phenothiazines as commonly used in surgical practice.

CONTRAINDICATIONS

ALFAXAN MULTIDOSE IDX is contraindicated in animals with a known sensitivity to ALFAXAN MULTIDOSE IDX or its components, or when general anesthesia and/or sedation are contraindicated. Do not use in any minor species animal that may become eligible for consumption by humans or food-producing animals.

WARNINGS

**Animal Safety:** Rapid bolus administration or anesthetic overdose may cause cardiorespiratory depression, including hypotension, apnea, hypoxia, or death. Arrhythmias may occur secondary to apnea and hypoxia. In cases of anesthetic overdose, stop ALFAXAN MULTIDOSE IDX administration and administer treatment as indicated by the patient's clinical signs. Cardiovascular depression should be treated with plasma expanders, pressor agents, anti-arrhythmic agents or other techniques as appropriate for the treatments of the clinical signs.

**Human safety:** Not for human. Keep out of the reach of children.

ALFAXAN MULTIDOSE IDX should be managed to prevent the risk of diversion, through such measures as restriction of access and the use of drug accountability procedures appropriate to the clinical setting. Exercise caution to avoid accidental self-injection. Overdose is likely to cause cardiorespiratory depression (such as hypotension, bradycardia and/or apnea). Remove the individual from the source of exposure and seek medical attention. Respiratory depression should be treated by artificial ventilation and oxygen. Avoid contact of this product with skin, eyes, and clothes. In case of contact, eyes and skin should be liberally flushed with water for 15 minutes. Consult a physician if irritation persists. In the case of accidental human ingestion, seek medical advice immediately and show the package insert or the label to the physician.

The Safety Data Sheet (SDS) contains more detailed occupational safety information. To report adverse reactions in users or to obtain a copy of the SDS for this product call 1-888-963-8471.

**Note to physician:** This product contains an injectable anesthetic.

**DRUG ABUSE AND DEPENDENCE**

**Controlled substance:** ALFAXAN MULTIDOSE IDX contains alfaxalone, a neurosteroid anesthetic and a class IV controlled substance.

**Abuse:** Alfaxalone is a central nervous system depressant that acts on GABA receptor associated chloride channels, similar to the mechanism of action of Schedule IV sedatives such as benzodiazepines (diazepam and midazolam), barbiturates (phenobarbital and methohexitol) and fosfopropofol. In drug discrimination behavioral test in rats, the effects of alfaxalone were recognized as similar to those of midazolam. These biochemical and behavioral data suggest that alfaxalone has an abuse potential similar to other Schedule IV sedatives.

**Physical dependence:** There are no data that assess the ability of alfaxalone to induce physical dependence. However, alfaxalone has a mechanism of action similar to the benzodiazepines and can block the behavioral responses associated with precipitated benzodiazepine withdrawal. Therefore, it is likely that alfaxalone can also produce physical dependence and withdrawal signs similar to those produced by the benzodiazepines.

**Psychological dependence:** The ability of alfaxalone to produce psychological dependence is unknown because there are no data on the rewarding properties of the drug from animal self-administration studies or from human abuse potential studies.

Black ●


**PRODUCT: US-Alfazan Multidose IDX - LFT - 471645**

**MODIFICATION DATE: 20 April 2023 1.22 pm**


**DIMENSIONS: 240 x 224 mm spread (folded to 120 x**



PRODUCT: CARTON ALFAXAN MULTIDOSE IDX 10ML US ZOETIS				PART NUMBER: 471650	
FILE NAME: US - Alfaxan Multidose IDX - CTN - 10 mL - 471650	DATE MODIFIED: 14/04/2023, 8.05 pm	COLOUR: CMYK	186	VARNISH FREE AREA: YES	PRINTER: MCC KNIFE: P02208
DIMENSIONS: 34 x 34 x 70.5 mm	UPS GTIN: 087219711811	BLACK	281	VFA	
JUROX FG Code: JX_520805_US	ZOETIS SAP FG CODE: 10026698				
This artwork is created and managed internally by Jurox. For external enquiries, please email <a href="mailto:purchasing@jurox.com.au">purchasing@jurox.com.au</a> .					



PRODUCT: <b>LABEL ALFAXAN MULTIDOSE IDX 10ML US ZOETIS</b>		PART NUMBER: <b>471640</b>		
FILE NAME: US - Alfaxan Multidose IDX - LBL - 10 mL - 471640 DATE MODIFIED: 14/04/2023, 6.48 pm DIMENSIONS: 70 x 28 mm GTIN: n/a JUROX FG Code: JX_520805_US ZOETIS SAP FG CODE: 10026698	COLOUR: CMYK BLACK 186 281	VARNISH FREE AREA: YES VFA This artwork is created and managed internally by Jurox. For external enquiries, please email <a href="mailto:purchasing@jurox.com.au">purchasing@jurox.com.au</a> .	PRINTER: MCC KNIFE: P02208	



PRODUCT: **OUTER CARTON ALFAXAN MULTIDOSE 10ML US ZOET**

PART NUMBER: **471655**

FILE NAME: US - Alfaxan Multidose IDX - OUT - 10 mL - 47165  
DATE MODIFIED: 17/04/2023, 11.28 am  
DIMENSIONS: L 175 mm, W 70 mm, D 75 mm  
GTIN: N/A  
JUROX FG Code: JX\_520805\_US  
ZOETIS SAP FG CODE: 10026698

VARNISH FREE AREA: NO PRINTER: MCC  
VFA  KNIFE: P02

This artwork is created and managed internally by Jurox. For external enquiries, please email [purchasing@jurox.com](mailto:purchasing@jurox.com)

**Jurca**  
Part of Zeta

Manufactured in Australia  
by Jurox Pty Limited

**zoetis**

Distributed by:

Zoetis Inc.

Kalamazoo, MI 49007



30087219711812

ITEM CODE

**520805**

**10026698**

---

LOT NUMBER

**XXXXX**



EXPIRY DATE

**yyyy-MMM**


QUANTITY

**400**

Store at controlled room temperature  
20 - 25 degrees C (68 - 77 degrees F)  
PROTECT FROM FREEZING




PRODUCT: CARTON ALFAXAN MULTIDOSE IDX 20ML US ZOETIS				PART NUMBER: 471665	
FILE NAME:	US - Alfaxan Multidose IDX - CTN - 20 mL - 471665	COLOUR:	CMYK		PRINTER: MCC
DATE MODIFIED:	14/04/2023, 8.20 pm	BLACK	281		KNIFE: P02208
DIMENSIONS:	34 x 34 x 70.5 mm	186			
UPS GTIN:	087219711828	VFA			
JUROX FG Code:	JX_520810_US	This artwork is created and managed internally by Jurox. For external enquiries, please email <a href="mailto:purchasing@jurox.com.au">purchasing@jurox.com.au</a> .			
ZOETIS SAP FG CODE:	10026695				



70 mm

28 mm

PRODUCT: <b>LABEL ALFAXAN MULTIDOSE IDX 20ML US ZOETIS</b>		PART NUMBER: <b>471660</b>	
FILE NAME: US - Alfaxan Multidose IDX - LBL - 20 mL - 471660 DATE MODIFIED: 14/04/2023, 6.50 pm DIMENSIONS: 70 x 28 mm GTIN: n/a JUROX FG Code: JX_520810_US ZOETIS SAP FG CODE: 10026695	COLOUR: CMYK BLACK 186 281	VARNISH FREE AREA: YES VFA This artwork is created and managed internally by Jurox. For external enquiries, please email <a href="mailto:purchasing@jurox.com.au">purchasing@jurox.com.au</a> .	PRINTER: MCC KNIFE: P02208 



PRODUCT: OUTER CARTON ALFAXAN MULTIDOSE 10 X 20ML US ZOETIS		PART NUMBER: 471670	
FILE NAME:	US - Alfaxan Multidose IDX - OUT - 20 mL - 471670	COLOUR: CMYK	
DATE MODIFIED:	17/04/2023, 11.42 am	BLACK  281 	
DIMENSIONS:	L 175 mm, W 70 mm, D 75 mm	186 	VARNISH FREE AREA: NO VFA 
GTIN:	N/A		PRINTER: MCC KNIFE: P02581
JUROX FG Code:	JX_520810_US		
ZOETIS SAP FG CODE:	10026695		
This artwork is created and managed internally by Jurox. For external enquiries, please email <a href="mailto:purchasing@jurox.com.au">purchasing@jurox.com.au</a> .  Part of Zoetis			

Manufactured in Australia  
by Jurox Pty Limited

**zoetis**

Distributed by:

Zoetis Inc.

Kalamazoo, MI 49007



30087219711829

ITEM CODE

**520810**

**10026695**

---

LOT NUMBER

**12345**



EXPIRY DATE

**2025-SEP**

QUANTITY

**400**

Store at controlled room temperature  
20 - 25 degrees C (68 - 77 degrees F)  
PROTECT FROM FREEZING